Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial

Federica Cappuccini; Richard Bryant; Emily Pollock; Lucy Carter; Clare Verrill; Julianne Hollidge; Ian Poulton; Megan Baker; Celia Mitton; Andrea Baines; Armin Meier; Guenter Schmidt; Richard Harrop; Andrew Protheroe; Ruth MacPherson; Steven Kennish; Susan Morgan; Selena Vigano; Pedro J Romero; Thomas Evans; James Catto; Freddie Hamdy; Adrian V S Hill; Irina Redchenko

doi:10.1136/jitc-2020-000928

Article info

PDF

XML

Clinical/translational cancer immunotherapy

Original research

Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial

Authors

Federica Cappuccini Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK PubMed articles Google scholar articles
Richard Bryant Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK Department of Urology, Churchill Hospital, Oxford, UK PubMed articles Google scholar articles
Emily Pollock Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK PubMed articles Google scholar articles
Lucy Carter Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK PubMed articles Google scholar articles
Clare Verrill Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK Oxford NIHR Biomedical Research Centre, Oxford University, Oxford, UK PubMed articles Google scholar articles
Julianne Hollidge Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK PubMed articles Google scholar articles
Ian Poulton Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK PubMed articles Google scholar articles
Megan Baker Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK PubMed articles Google scholar articles
Celia Mitton Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK PubMed articles Google scholar articles
Andrea Baines Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK PubMed articles Google scholar articles
Armin Meier Definiens AG, Munchen, Bayern, Germany PubMed articles Google scholar articles
Guenter Schmidt Definiens AG, Munchen, Bayern, Germany PubMed articles Google scholar articles
Richard Harrop Oxford Biomedica Plc, Oxford, UK PubMed articles Google scholar articles
Andrew Protheroe Department of Oncology, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, UK PubMed articles Google scholar articles
Ruth MacPherson Department of Radiology, Churchill Hospital, Oxford, UK PubMed articles Google scholar articles
Steven Kennish Department of Radiology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK PubMed articles Google scholar articles
Susan Morgan Department of Pathology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK PubMed articles Google scholar articles
Selena Vigano Oncology, University Hospital of Lausanne, Lausanne, Switzerland PubMed articles Google scholar articles
Pedro J Romero Oncology, University Hospital of Lausanne, Lausanne, Switzerland PubMed articles Google scholar articles
Thomas Evans Vaccitech UK Limited, Oxford, UK PubMed articles Google scholar articles
James Catto Academic Urology Unit, The University of Sheffield, Sheffield, UK PubMed articles Google scholar articles
Freddie Hamdy Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK Department of Urology, Churchill Hospital, Oxford, UK PubMed articles Google scholar articles
Adrian V S Hill Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK PubMed articles Google scholar articles
Irina Redchenko Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK PubMed articles Google scholar articles

Citation

Cappuccini F, Bryant R, Pollock E, et al

Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial

Journal for ImmunoTherapy of Cancer 2020;8:e000928. doi: 10.1136/jitc-2020-000928

Online issue publication

January 11, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password